Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Curr Opin Oncol. 2011 Nov;23(6):587-93. doi: 10.1097/CCO.0b013e32834bb8a7.
This article reviews the current knowledge of therapeutic targeting of CD30+ cancers using naked and conjugated monoclonal antibodies.
After unsuccessful outcome of early trials using naked and conjugated anti-CD30 antibodies, substantial progress was achieved with the development of the antibody-drug-conjugate brentuximab vedotin. In two recently completed phase II studies in patients with relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL), the single agent response rates were 75 and 86%, respectively. These impressive results led to the recommendation of the Oncology Drug Advisory Committee for an accelerated approval of brentuximab vedotin by the Food and Drug Administration.
Brentuximab vedotin demonstrated the most potent single agent activity for the treatment of patients with relapsed Hodgkin lymphoma and ALCL. Incorporating brentuximab vedotin with frontline regimens is currently being evaluated in clinical trials.
本文综述了使用裸单抗和偶联单抗靶向治疗 CD30+癌症的最新进展。
在使用裸抗 CD30 抗体和偶联抗体的早期试验失败后，随着抗体药物偶联物 Brentuximab vedotin 的开发，取得了实质性的进展。在两项最近完成的复发霍奇金淋巴瘤和系统性间变性大细胞淋巴瘤（ALCL）患者的 II 期研究中，单药治疗的反应率分别为 75%和 86%。这些令人印象深刻的结果促使肿瘤药物咨询委员会建议美国食品和药物管理局加速批准 Brentuximab vedotin。
Brentuximab vedotin 显示出治疗复发霍奇金淋巴瘤和 ALCL 患者最有效的单药活性。目前正在临床试验中评估将 Brentuximab vedotin 与一线方案联合使用。
